AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 922328
Drug: 2000 IU
RxNorm normalized name: D 2000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 IU vitamin D daily
Trial: 26714522
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (treatment-as-usual)
Trial: 19863739
Drug: Reduced-dose rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose rocuronium (0.45 mg x kg(‐1))
Trial: 19863739
Drug: Standard-dose rocuronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose rocuronium (0.6 mg.kg(‐1))
Trial: 17564674
Drug: Whole Body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole Body Vibration (WBV) at 30 Hz; 3.5 g (1 g=9.81 m.s2)
Trial: 16282676
Drug: Doxercalciferol at
RxNorm normalized name: Doxercalciferol
DrugBank: Doxercalciferol (DB06410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxercalciferol at 35%, 50%, or 65% of paricalcitol dose for 6 weeks
Trial: 12242054
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg and 1200 mg mifepristone
Trial: 10235156
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m2 per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 11)
Trial: 10235156
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (in the nonrandomized part)
Trial: 10235156
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy and RT only
Trial: 6123287
Drug: Oxatomide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (30 mg bid)
Trial: 21287904
Drug: Concurrent peer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent peer review visits
Trial: 12759845
Drug: Prophylaxis treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis treatments
Trial: 9527146
Drug: 24 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 g/day piracetam
Trial: 9527146
Drug: 16.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16.8 g/day piracetam
Trial: 9527146
Drug: 9.6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9.6 g/day piracetam
Trial: 7605861
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of famotidine 40 mg/day
Trial: 7246468
Drug: Hypnotic sensory
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic sensory imagery conditioning program (three-week duration, daily sessions with three conditioning images and self-hypnotic practice)
Trial: 24450252
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin (TAM) 0.4 mg daily
Trial: 24450252
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens (SR) 320 mg daily
Trial: 24450252
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin (TAM) 0.4 mg daily + Serenoa repens (SR) 320 mg daily
Trial: 21404452
Drug: Continuous low-volume
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous low-volume infusion of hydroxyethyl starch (HES) at a dose of 15 ml/kg/day
Trial: 12162272
Drug: Algorithm dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm dosing of acenocoumarol
Trial: 12162272
Drug: Routine dosing
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dosing of acenocoumarol
Trial: 2363117
Drug: i.v. low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. low-dose aspirin
Trial: 2363117
Drug: i.v. isosorbide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. isosorbide dinitrate and oral diltiazem
Trial: 12587621
Drug: 5 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 microg/kg per day of intravenous rGCSF once daily for 3 days
Trial: 29775141
Drug: Structured group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured group reminiscence therapy for 8 weeks
Trial: 23478699
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein diet (< 22% daily energy intake) + Resistance Training (RT)
Trial: 23478699
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein diet (> 22% daily energy intake) + Resistance Training (RT)
Trial: 23478699
Drug: Lower protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower protein diet (< 22% daily energy intake) + Habitual activity (Control)
Trial: 23478699
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein diet (> 22% daily energy intake) + Habitual activity (Control)
Trial: 20034682
Drug: Injected activated
RxNorm normalized name: eptacog alfa activated Injection [Novoseven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected activated macrophage suspension (AMS)
Trial: 12011547
Drug: Echovist-300 with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echovist-300 with VM for 5 s starting 5 s after injection
Trial: 12011547
Drug: Echovist-200 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echovist-200 with VM for 5 s starting 5 s after injection
Trial: 12011547
Drug: Echovist-300 with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echovist-300 with VM for 5 s starting with the beginning of injection
Trial: 12011547
Drug: Echovist-300 with
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echovist-300 with VM for 5 s starting 10 s after injection
Trial: 12011547
Drug: Echovist-200 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echovist-200 with VM for 5 s starting with the beginning of injection
Trial: 10424515
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (RATG) induction therapy (1.5 mg/kg/d for 3 days)
Trial: 10424515
Drug: Conventional immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunosuppression alone (no induction therapy)
Trial: 10424515
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (RATG) induction therapy
Trial: 31627773
Drug: Antimicrobial agents
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial agents (specific agents not detailed)
Trial: 29307310
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green coffee bean extract (GCE) 400 mg twice per day for 8 weeks
Trial: 27175447
Drug: Heat-killed Lactobacillus
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed Lactobacillus plantarum L-137 (HK L-137) 10 mg daily for 12 weeks
Trial: 30917927
Drug: BAY 85-8501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 85-8501 (1 mg once daily for 28 days)
Trial: 25933488
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (7000 μg retinol equivalents)
Trial: 19928386
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (fixed sleep schedule consistent with average baseline, no TIB restriction)
Trial: 16355285
Drug: Bumetanide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide (2 mg/day)
Trial: 11125713
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg glycyrrhizic acid/kg body weight
Trial: 11125713
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg glycyrrhizic acid/kg body weight
Trial: 11125713
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg glycyrrhizic acid/kg body weight
Trial: 11125713
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg glycyrrhizic acid/kg body weight
Trial: 9042977
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 500 mg b.d.
Trial: 9042977
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg q.d.s.
Trial: 29901507
Drug: Pulsed electromagnetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed electromagnetic fields (PEMF) treatment
Trial: 30316696
Drug: Dexketoprofen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen (1 mg kg–1 IV; administered every 8 hours)
Trial: 30316696
Drug: Methadone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (0.2 mg kg–1 IV; administered every 4 hours)
Trial: 19034870
Drug: Epoetin-alpha (EPO-alpha)
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha (EPO-alpha) to maintain hemoglobin levels in the range 12-14 g/dL, median final dose 2,000 IU/week.
Trial: 19034870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment unless hemoglobin decreased to 9.0 g/dL).
Trial: 19034870
Drug: Epoetin-alpha (EPO-alpha)
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha (EPO-alpha) treatment group.
Trial: 17163135
Drug: Twinrix and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twinrix and monovalent vaccines
Trial: 2082318
Drug: Acetaminophen-codeine 600
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen-codeine 600 mg plus 60 mg
Trial: 117953
Drug: Insulin induced
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin induced hypoglycaemia
Trial: 27931291
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 µg once daily (n = 25)
Trial: 16332600
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5FU/levamisole for 12 months, n = 444; 5FU/leucovorin for 4-5 months, n = 262; 5FU/leucovorin with +/- levamisole, n = 397)
Trial: 12006716
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate 300 microg 6 times daily for 2 years
Trial: 12006716
Drug: Subcutaneous Suprefact
RxNorm normalized name: Suprefact
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Suprefact Depot 6.3 mg every 8 weeks for the third year
Trial: 12006716
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment in addition to pubertal inhibition (randomized in half of the girls)
Trial: 15159227
Drug: Moderate n-6
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Trial: 15159227
Drug: High n-6
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High n-6 PUFA diet + 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid)
Trial: 15159227
Drug: 4.0 g
RxNorm normalized name: Menthol 4.0 g in 100 mL TOPICAL GEL [BIOCOOL ROLL TYPE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 g fish oil/d (2.5 g eicosapentaenoic acid + docosahexaenoic acid) after 6 weeks of dietary intervention
Trial: 11953878
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg intravenous clodronate
Trial: 11953878
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg intravenous clodronate
Trial: 11953878
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg intravenous clodronate
Trial: 11953878
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg intravenous clodronate
Trial: 2146057
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg every 12 hours)
Trial: 369651
Drug: Acarbose (alpha-glucosidehydrolase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (alpha-glucosidehydrolase inhibitor) taken with food
Trial: 30986302
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 16.1 mg of ASAL‐HM
Trial: 30986302
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 8.0 mg of HM (control)
Trial: 30986302
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of ASAL‐HM
Trial: 30055692
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection with 40 mg triamcinolone acetonide
Trial: 30055692
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection with 1.25 mg bevacizumab
Trial: 30055692
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of subconjunctival triamcinolone acetonide and intravitreal bevacizumab
Trial: 27817811
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 9/9.6 μg
Trial: 27817811
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 4.6/9.6 μg
Trial: 27817811
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 2.4/9.6 μg
Trial: 27817811
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 1.2/9.6 μg
Trial: 27817811
Drug: Open-label tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label tiotropium 18 μg
Trial: 22301084
Drug: Buprenorphine induction
RxNorm normalized name: buprenorphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine induction for prescription opioid users
Trial: 10436979
Drug: Zhuling polysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuling polysaccharides combined with hepatitis B vaccine (group I)
Trial: 10436979
Drug: LAK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAK cells induced by interleukin‐2 (IL‐2) transfusion therapy (group II)
Trial: 29279299
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic therapy (target HbA1c <6.0%)
Trial: 27494777
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol 400 mg every 4 weeks for ≤7.5 years
Trial: 24728846
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (ESWT) - 6000 impulses (energy flux density, 0.11 mJ/mm²) in three sessions after local anesthesia.
Trial: 19962288
Drug: Silexan (lavender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silexan (lavender oil preparation), 6-week intake
Trial: 18541280
Drug: Tafenoquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg bid for 3 days
Trial: 18541280
Drug: Tafenoquine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 400 mg od for 3 days
Trial: 18541280
Drug: Primaquine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine plus doxycycline (22.5 mg + 100 mg daily for 14 days)
Trial: 18541280
Drug: Tafenoquine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafenoquine 200 mg od for 3 days
Trial: 8869096
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care plus MLT (20 mg/day orally in the evening)
Trial: 8465554
Drug: Saccharomyces boulardii
RxNorm normalized name: Saccharomyces boulardii
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saccharomyces boulardii (S.b.) 250 mg t.i.d. for 7 weeks
Trial: 27376907
Drug: Lidocaine gel
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine gel (10 ml)
Trial: 19274410
Drug: Focus Monthly
RxNorm normalized name: Ficus benghalensis bark extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focus Monthly (Ciba Vision)
Trial: 17146319
Drug: ORAL rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORAL rehydration
Trial: 10924977
Drug: Conventionally fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventionally fractionated (cf) treatment: 60 Gy over 6 weeks (n = 79)
Trial: 1405361
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of hypertension to blood pressure values within the normal range
Trial: 1405361
Drug: Low-protein diets
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diets with ketoacid supplement
Trial: 1405361
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment of hyperlipidemia
Trial: 31197986
Drug: MenACWY-CRM197 conjugate
RxNorm normalized name: Neisseria meningitidis serogroup A oligosaccharide diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM197 conjugate vaccine
Trial: 31197986
Drug: MenACWY-DT conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MenACWY-DT conjugate vaccine
Trial: 29100777
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tibial tubercle lateralization and patella alta
Trial: 27358434
Drug: High-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose edoxaban regimen (HDER) 60 mg daily or 30 mg daily for CrCl 30-50 mL/min
Trial: 27358434
Drug: High-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose edoxaban regimen (HDER)
Trial: 20438400
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.033 mg/kg/day
Trial: 20438400
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) 0.067 mg/kg/day
Trial: 12016800
Drug: Indapamide (2.5‐7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide (2.5‐7.5 mg.d‐1)
Trial: 12016800
Drug: Dihydro-chlorothiazide (50‐70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydro-chlorothiazide (50‐70 mg.d‐1)
Trial: 12016800
Drug: Carbamazepine (150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (150‐300 mg.d‐1)
Trial: 8824659
Drug: Polyunsaturated phosphatidyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated phosphatidyl choline (900 mg orally daily)
Trial: 1614464
Drug: Standard immune
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard immune globulin (400 mg per kilogram of body weight)
Trial: 1614464
Drug: Core-lipopolysaccharide hyperimmune
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core-lipopolysaccharide hyperimmune globulin (400 mg per kilogram)
Trial: 1614464
Drug: Placebo (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (25 percent albumin, 8 ml per kilogram)